WINNIPEG, MANITOBA--(Marketwire - Feb. 21, 2013) - Kane Biotech Inc. (TSX VENTURE:KNE), is very pleased to report that there is a strong rate of support and adoption from veterinarians for the recently announced marketing field test for StrixNB in Manitoba. Many veterinarians are now recommending StrixNB to their clients as an important part of a regular pet oral care program. Kane Biotech is a biotechnology company engaged in the development and commercialization of products that prevent and remove microbial biofilms. On January 31, 2013 the company announced that it launched its marketing field test for StrixNB, its revolutionary new pet oral care product in Manitoba in conjunction with Pet Dental Health Month.
The response to the marketing field test has been very positive with 84% of the veterinary clinics in Manitoba signing up for the Company's promotional campaign that coincides with February's Pet Oral Care month. In addition, in the first two weeks, 48% of these clinics have already placed orders to regularly carry StrixNB in their clinics. Commercial manufacturing was successfully completed to supply demand for further expansion across Canada. Accounting and financial procedures are in place from purchasing raw materials to inventory management to account collecting from distribution. In addition Standard Operating Procedures (SOP's) have been developed and are in place for manufacturing and operations and quality control procedures have been implemented.
With very encouraging acceptance from both veterinarians and consumers the Company is now in the process of developing additional product applications such as toothpastes and dental chews.
About Kane Biotech Inc.
Kane Biotech is a biotechnology company engaged in the development and commercialization of products that prevent and remove biofilms. Biofilms develop when bacteria and other microorganisms form a protective matrix that acts as a shield against attack. When in a biofilm, bacteria become highly resistant to antibiotics, biocides, disinfectants, high temperatures and host immune responses. This resiliency contributes to human health problems such as recurrent urinary tract infections, medical device associated infections and tooth decay.
Kane Biotech uses patent protected technologies based on molecular mechanisms of biofilm formation/dispersal and methods for finding compounds that inhibit or disrupt biofilms. The Company has evidence that these technologies have potential to significantly improve the ability to prevent and/or destroy biofilms in several medical and industrial applications.
Caution Regarding Forward-Looking Information
Certain statements contained in this press release constitute forward-looking information within the meaning of applicable Canadian provincial securities legislation (collectively, "forward-looking statements"). These forward-looking statements relate to, among other things, our objectives, goals, targets, strategies, intentions, plans, beliefs, estimates and outlook, including, without limitation, our anticipated future operating results, and can, in some cases, be identified by the use of words such as "believe", "anticipate", "expect", "intend", "plan", "will", "may" and other similar expressions. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements.
These statements reflect management's current beliefs and are based on information currently available to management. Certain material factors or assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. Important factors that could cause actual results to differ materially from these expectations include, among other things: Kane's early stage of development, lack of product revenues and history of operating losses, uncertainties related to clinical trials and product development, rapid technological change, uncertainties related to forecasts, competition, potential product liability, additional financing requirements and access to capital, unproven markets, supply of raw materials, income tax matters, management of growth, partnerships for development and commercialization of technology, effects of insurers' willingness to pay for products, system failures, dependence on key personnel, foreign currency risk, risks related to regulatory matters and risks related to intellectual property and other risks detailed from time to time in Kane's filings with Canadian securities regulatory authorities, as well as Kane's ability to anticipate and manage the risks associated with the foregoing. Kane cautions that the foregoing list of important factors that may affect future results is not exhaustive. When relying on Kane's forward-looking statements to make decisions with respect to Kane, investors and others should carefully consider the foregoing factors and other uncertainties and potential events.
These risks and uncertainties should be considered carefully and prospective investors should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in this press release are based upon what management believes to be reasonable assumptions, Kane cannot provide assurance that actual results will be consistent with these forward-looking statements. Kane undertakes no obligation to update or revise any forward-looking statement.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.